There is a small error in presentation of Fig. 1. The correct figure (Fig. 1) is
Fig. 1
Competing models of memory T cell differentiation. A Plots depict the clonal expansion of antigen-specific CD8+ T cells in response to infection and their differentiation from naïve to effector to memory cells (Model I, left), as well as the predicted division histories of effector and memory subsets (right). B As in A, but showing the differentiation of naïve CD8+ T cells first into memory and then effector cells (Model II). C. Progressive model of CD8+ T cell differentiation, based on in vivo single cell fate mapping and population-derived data. Selected markers characterizing naïve, central memory precursor (CMP), effector memory precursor (EMP) and short-lived/terminal effector (SLEC/TE) cells are shown, as are the distinct functional properties of these subsets and a predicted increase of cell cycle speed upon transition from naïve to CMP, EMP and SLEC/TE cells
×
Anzeige
The original article has been corrected.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Auch für Trägerinnen von BRCA-Varianten gilt: Erkranken sie fünf bis zehn Jahre nach der letzten Schwangerschaft an Brustkrebs, ist das Sterberisiko besonders hoch.
Eine hypertherme intravesikale Chemotherapie mit Mitomycin kann für Patienten mit hochriskantem nicht muskelinvasivem Blasenkrebs eine Alternative zur radikalen Zystektomie darstellen. Kölner Urologen berichten über ihre Erfahrungen.
Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.
Immer mehr jüngere Menschen leiden unter Vorhofflimmern. Betroffene unter 65 Jahren haben viele Risikofaktoren und ein signifikant erhöhtes Sterberisiko verglichen mit Gleichaltrigen ohne die Erkrankung.
Update Innere Medizin
Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.
